Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Soralex** is a multi-ingredient topical cream developed and evaluated in Ecuador for mild-to-moderate psoriasis, including plaque psoriasis. The formulation contains salicylic acid, animal lard, sublimed sulfur, potassium aluminum sulfate, petrolatum, and bay essential oil. Its intended effects are primarily local and physicochemical: salicylic acid and sulfur provide keratolytic and desquamating activity, while petrolatum and lard provide emollient and occlusive skin-barrier support; sulfur, alum, and bay essential oil were intended to contribute antimicrobial, astringent, soothing, and anti-inflammatory effects. A randomized controlled clinical study compared twice-daily application of the cream with topical betamethasone over 10 days and reported improvement in erythema, infiltration, desquamation, pruritus, PASI, and affected body-surface area. The product was reported as commercially authorized in Ecuador in February 2023.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Soralex.